Table 3 In Vitro CD8 T Cell Response against Telomerase Peptides in Cancer Patients
HLA Allele | hTRT peptide | Tumor type | Killing of tumor cells | Tumor infiltrating lymphocytes | Cancer Patient in vitro PBMC immunization R/T | Ref. | |
|---|---|---|---|---|---|---|---|
| Â | Â | Â | Autologous primary tumor cells | Established tumor cell lines | Â | Â | Â |
A2 | p540 | Prostate | ND | T2*, LnCap | ND | 6/9 (66%) | [30] |
| Â | Â | Melanoma | ND | T2* | ND | 1/4 (25%) | (unpublished data) |
| Â | Â | Hematological malignancies and advanced prostate | NHL | ND | ND | 5/6 (83%) | [73] |
| Â | Â | Prostate, Breast, Lung, Gastric, NHL, Liver | Prostate cancer cells | ND | ND | 21/23 (91%) | [67] |
| Â | Â | Breast | ND | ND | ND | 11/14 (79%) | [69] |
| Â | Â | Colorectal | Colorectal cancer cells | ND | ND | 5/37 (13%) | [68] |
| Â | pY572 | Prostate | ND | T2* | ND | 5/8 (62%) | (unpublished data) |
| Â | p865 | Colorectal | Colorectal cancer cells | ND | ND | 4/37 (11%) | [68] |
| Â | Â | Breast | ND | ND | ND | 6/14 (43%) | [69] |
| Â | Â | Prostate | ND | T2* | ND | 3/6 (50%) | (unpublished data) |
| Â | Â | Melanoma | Â | Â | Â | 2/3 (67%) | Â |
B7 | p1123 | Prostate | ND | T2-B7* | ND | 2/2 (100%) | [70] |
A3 | p973 | Breast | U266, SK-MES-1, SK-MEL-2, NHL | T2-A3*, | ND | 4/7 (57%) | [69] |
A24 | p1008 | Liver | ND | HepG2, HuH6 and HuH7 (Hepatoma) | ND | 6/72 (8%) | [76] |
| Â | p845 | Â | Â | Â | Â | 6/72 (8%) | Â |
| Â | p167 | Â | Â | Â | Â | 9/72(13%) | Â |
| Â | p461 | Â | Â | Â | + | 5/72 (7%) | Â |
| Â | p324 | Â | Â | Â | ND | 9/72 (13%) | Â |
| Â | p637 | Â | Â | Â | Â | 9/72 (13%) | Â |